NASDAQ$HUMA
Humacyte Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments.
Humacyte reported no revenue for Q2 2023. Enrollment was completed in the Phase 2/3 V005 trial of HAV™ in Vascular Trauma Repair. Top-line results are expected in Q3 2023, followed by a planned BLA filing in Q4 2023. Cash and cash equivalents were $114.6 million as of June 30, 2023.
- Completed enrollment in Phase 2/3 clinical trial of HAV in vascular trauma repair.
- Presented success in treating wartime injured in Ukraine using HAV under humanitarian aid program.
- Published study supporting infection resistance of HAV in the Journal of Vascular Surgery – Vascular Science.
- Advanced Type 1 Diabetes Research through collaboration with JDRF International to develop Biovascular Pancreas (BVP).
Headline financials
Revenue & EPS history
Humacyte · Revenue · Quarterly
$0
Forward guidance
Humacyte believes that its cash and cash equivalents and expected funding from the Oberland funding agreement are adequate to fund operations past the anticipated timelines for potential FDA approval and commercialization of the HAV in the vascular trauma indication.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+5.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+37.0%
Q2 2023
Best reaction
-30.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +22.9% | -1.5% | +15.2% | |
| Q4 2025 | -15.1% | -25.1% | -33.0% | |
| Q3 2025 | -3.2% | -11.7% | +2.3% | |
| Q2 2025 | -30.1% | -24.2% | -40.3% | |
| Q1 2025 | +19.5% | +23.8% | +25.4% | |
| Q4 2024 | -2.5% | -27.4% | -28.4% | |
| Q3 2024 | +4.9% | +1.5% | -8.2% | |
| Q1 2024 | +21.2% | +43.1% | +60.8% | |
| Q4 2023 | -12.8% | -13.9% | +2.8% | |
| Q3 2023 | +7.3% | +9.1% | +27.9% | |
| Q2 2023 | +37.0% | +8.9% | +19.0% | |
| Q1 2023 | -6.1% | -2.5% | +1.1% | |
| Q4 2022 | +4.9% | -1.3% | +7.1% | |
| Q3 2022 | +2.2% | -5.4% | -4.5% | |
| Q2 2022 | +8.6% | +9.1% | +2.5% | |
| Q1 2022 | -9.5% | -12.7% | -18.8% | |
| Q4 2021 | +14.1% | +12.2% | +16.5% | |
| Q2 2021 | +14.1% | +12.2% | +16.5% | |
| Q3 2021 | +9.0% | +18.4% | +4.0% | |
| Q1 2021 | +0.0% | +0.0% | +4.9% | |
| Q4 2020 | +21.2% | +28.4% | +1.5% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro